-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30

PUBT·04/27/2026 00:00:41
Listen to the news
Ascletis completes enrollment in US Phase II diabetes trial of oral GLP-1 drug ASC30
  • Ascletis completed enrollment in a 13-week U.S. Phase II trial of ASC30, its once-daily oral small-molecule GLP-1 receptor agonist, in 100 patients with type 2 diabetes.
  • Topline results have not been presented yet; data are expected in Q3 2026.
  • Trial is designed to assess whether ASC30 can improve blood sugar control versus placebo, with additional readouts on weight change and overall safety.
  • Program expansion adds a second major indication for ASC30 beyond obesity, positioning it for a larger metabolic disease market opportunity.
  • Ascletis expects to seek FDA clearance to start U.S. Phase III trials in obesity by end-Q3 2026, following previously disclosed Phase II obesity results from December 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260427-12123617), on April 27, 2026, and is solely responsible for the information contained therein.